drugset / Trial / NCT02230891

Biomarker Guided Therapies in Stage A/B Heart Failure

NCT02230891

RandomizedParallel-groupOpen-labelPrevention

Summary

Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore, prevention of HF is essential. HF prevention is a critical issue as HF risk factors that include common medical conditions such as hypertension and diabetes are also increasing. However, not everyone with these risk factors develops HF. Using novel blood tests, the investigators propose to identify and treat subjects at higher HF risk to see if the investigators can stabilize or improve ultrasound measures known to be associated with HF risk. This study will enroll only Veterans.

Timeline

Start
2014-10-01
Primary completion
2020-12-15
Completion
2020-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carvedilol Other / unclassified
Comparator Spironolactone Small molecule